Healthcare policy and patient access

PhRMA's Estimated $58.8M Search Advertising Campaign: Drug Pricing, PBMs and Patient Access

A 2026 study models PhRMA's $58.8 million search ad campaign. Explore PBM messaging, methodology limits, drug pricing policy and oncology patient access.

By Lampgen Clinical Research

Editorial illustration of a pharmacist handing medication to a patient above a phone with sponsored search results, with headline Drug Prices, Search Ads, Patient Access.
AI-generated editorial illustration, not an actual patient transaction or captured PhRMA ad. The $58.8M figure is a third-party research estimate; effects on opinion were not established.

4 min read · estimated

Sources
$58.8M estimated17.1M paid visits
Modeled paid-search activity from February 2019 to December 2025; these are not audited expenditures or demonstrated changes in opinion.

What the source reported

A peer-reviewed analysis published November 2, 2026, in Clinical Pharmacology & Therapeutics estimates that the Pharmaceutical Research and Manufacturers of America (PhRMA) spent $58.8 million on pay-per-click search advertising associated with phrma.org and its subdomains from February 2019 through December 2025. Using Semrush commercial digital-marketing data, the authors identified 283,517 keyword instances and estimated 17.1 million paid visits. These are model-derived metrics rather than disclosures from PhRMA's advertising accounts. [1]

The study categorized $32.4 million (55.1%) of estimated expenditure under insurance and health-plan search keywords; that classification included some general and non-health insurance terms. Separately, $27.9 million (47.5%) of estimated expenditure directed visitors to landing pages classified as critical of pharmacy benefit managers (PBMs). These are overlapping analytical classifications, not two disjoint spending buckets. Adding them together would be misleading. [1]

The researchers observed spending spikes near major U.S. drug-pricing policy developments. Estimated outlays reached $4.8 million in May 2023, and March–September 2023 accounted for 36.5% of the study-period total. This timing is consistent with a policy-focused advocacy strategy, but temporal coincidence alone does not prove that an advertising campaign caused a legislative outcome or changed what the public believes. The authors also found little linear association between monthly ad spending and their selected Google Trends measure (r = −0.05). [1]

PhRMA's position is that insurers, PBMs and other intermediaries materially contribute to patients' costs and coverage barriers. That argument warrants examination, not automatic dismissal. In January 2025, the Federal Trade Commission's staff reported sizable markups on certain specialty generic drugs dispensed by PBM-affiliated pharmacies. Its analysis of 51 specialty generics identified more than $7.3 billion in dispensing revenue above estimated drug acquisition costs for the largest three PBMs' affiliated pharmacies during 2017–2022. This FTC finding concerns a defined drug sample and period; it does not demonstrate that PBMs alone explain U.S. drug prices. [2, 3]

Manufacturers, insurers, PBMs, pharmacies, employers and public programs all affect the prices patients encounter through list pricing, negotiated rebates, benefit design, formulary placement, cost-sharing and distribution arrangements. A search advertisement can advance one part of that story. It cannot, by itself, resolve which mechanisms account for a specific patient's out-of-pocket bill. Medicare Part D's 2026 $2,100 annual out-of-pocket limit for covered drugs illustrates how policy design can alter the patient's financial exposure independently of any advertising narrative. [4]

What this means for trial teams

Why this matters: Search engines are often where patients first turn when a prescription is unaffordable, a claim is denied or a new medicine enters the market. Paid placements can shape which explanation appears first. It is important to identify the sponsor, examine the evidence behind the claim and distinguish an advocacy position from neutral patient guidance. The study documents an estimated campaign scale and targeting pattern; it did not directly measure actual belief changes, adherence or health outcomes.

Implications for oncology and specialty medicine: A scientifically effective treatment is not an accessible treatment until a patient can navigate coverage, specialty-pharmacy arrangements, prior authorization, cost-sharing and continuity of supply. Trial teams and sponsors should consider the practical access pathway as a separate question from clinical efficacy. These barriers may vary by insurance type, income, geography and patient support, making equitable implementation an evidence question—not a marketing assumption.

What sponsors and CROs can do: Design trial and transition workflows with clear patient-support boundaries, early identification of coverage and referral obstacles, appropriate informed-consent language, and reliable capture of reasons participants do not enroll or remain in care. Operational teams should avoid treating any single stakeholder's explanation of drug costs as a substitute for specific site, payer and patient information. CRAs support protocol compliance and timely escalation, while healthcare decisions and coverage determinations remain with the relevant clinical and payer professionals.

What policymakers and patients need: More transparent reporting of list versus net prices, rebates, patient cost-sharing and access restrictions; clear sponsorship labels on paid search messages; and independent evaluation of which reforms reduce actual patient spending and treatment delays. The debate should be anchored to outcomes that can be verified, not solely to who can purchase the most visibility.

Lampgen Clinical Research specializes in oncology CRA staffing and clinical-operations support. Our independent interpretation is simple: clinical innovation must be paired with credible evidence and a functioning path to patient access. We are not affiliated with the organizations evaluated in this study. The accompanying image is an AI-generated editorial scene and does not depict actual PhRMA advertising, a patient transaction or an observed clinical outcome. Analysis prepared November 6, 2026.

Sources

  1. 1. Eisenkraft Klein D, Kesselheim AS. Clinical Pharmacology & Therapeutics, November 2, 2026. DOI: 10.1002/cpt.70538
  2. 2. FTC — Second Interim Staff Report on Prescription Drug Middlemen, January 14, 2025
  3. 3. PhRMA — Cost of Medicines (industry position)
  4. 4. Medicare.gov — Part D costs and 2026 out-of-pocket limit
  5. 5. STAT — Report on the PhRMA search advertising study, November 5, 2026

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?